In Vitro Effects of Cyclosporine A and Tacrolimus on Regulatory T-Cell Proliferation and Function
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Liver transplantation is the treatment of end-stage liver diseases, including hepatitis C. Immunosuppression prevents graft rejection but seems to accelerate the recurrence of hepatitis C. Regulatory T cells (Tregs) may be beneficial in tolerance but deleterious in recurrent hepatitis C. We evaluated the effects of cyclosporine or tacrolimus, the principal immunosuppressive drugs, on Treg proliferation and function. METHODS: Human Tregs were isolated from healthy donors and cultured with cyclosporine, tacrolimus, or NIM811, a cyclosporine analog devoid of calcineurin-inhibiting activity. Treg proliferation and suppressive activity were assessed. The phenotype, cytokine production, and phosphorylation profile of nuclear factor of activated T cell of Tregs were also analyzed. RESULTS: Cyclosporine and tacrolimus both decreased Treg proliferation, but only low doses of cyclosporine reduced Treg activity, by inducing the production of interleukin 2 proinflammatory cytokines in these cells. Moreover, NIM811 also inhibited Treg activity. The phosphorylation of nuclear factor of activated T cell in Tregs was not altered by cyclosporine, suggesting that the effects of this drug are independent of the calcineurin pathway. CONCLUSION: In summary, low doses of cyclosporine inhibit Treg activity, a finding that might explain the beneficial effect of this drug on hepatitis C recurrence. In contrast, by maintaining Treg activity, tacrolimus could be more helpful than cyclosporine in controlling rejection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“one study showed that ciclosporin and tacrolimus inhibited Tregs proliferation and activation in vitro (60).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [60]
In the citing paper
“Ciclosporin and tacrolimus were found to inhibit Treg proliferation and activity in vitro (79), and similar effects were observed in tacrolimus-treated allograft patients ex vivo (80); this could be detrimental in inhibiting the development of peripheral tolerance following rAAV administration.”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [79]
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669 · cited 1×
“Tregs account for 5% to 10% of peripheral CD4 T cells; they constitutively express CD25 (3), can suppress host immune responses in the context of autoimmune diseases and transplantation (4, 5), and have been shown to be an essential component in immune tolerance (6).”
BackgroundThornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,639
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606 · cited 1×
“The transcription factor FoxP3, expressed by Tregs, seems to be a master gene controlling Treg development (8), most FoxP3 Tregs being CD127/low (9, 10).”
BackgroundA function for interleukin 2 in Foxp3-expressing regulatory T cells
Fontenot, J. D., Rasmussen, J. P., Gavin, M. A., & Rudensky, A. Y. (2005) · Nature Immunology · doi:10.1038/ni1263 · Cited by 1,819
Seddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S., Landay, A., Solomon, M., Selby, W., Alexander, S. I., Nanan, R., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060468 · Cited by 1,512 · cited 1×
“The transcription factor FoxP3, expressed by Tregs, seems to be a master gene controlling Treg development (8), most FoxP3 Tregs being CD127/low (9, 10).”
BackgroundSakaguchi, S., Sakaguchi, N., Shimizu, J., Yamazaki, S., Sakihama, T., Itoh, M., Kuniyasu, Y., Nomura, T., Toda, M., & Takahashi, T. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820102.x · Cited by 1,505
Itoh, M., Takahashi, T., Sakaguchi, N., Kuniyasu, Y., Shimizu, J., Otsuka, F., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.9.5317 · Cited by 1,211
Regulatory T cells and mechanisms of immune system control
O'Garra, A., & Vieira, P. (2004) · Nature Medicine · doi:10.1038/nm0804-801 · Cited by 810
Natural regulatory T cells: mechanisms of suppression
Miyara, M., & Sakaguchi, S. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.01.003 · Cited by 711
Research works printed but not linked: 2
- OGrady, 2007, Prognostication in acute liver failure: a tool or an anchor Liver T, ranspl, 6, 786
- Berenguer, 2002, Outcome of posttransplantation hepatitis C virus diseaseis it the host, the virus, or how we modify the host andor the virus Liver T, ranspl, 10, 889
Cited by
Calcineurin inhibitors: 40 years later, can’t live without
Azzi, J. R., Sayegh, M. H., & Mallat, S. G. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1390055 · Cited by 337
Effect of Nasopharyngeal Carcinoma-Derived Exosomes on Human Regulatory T Cells
Mrizak, D., Martin, N., Barjon, C., Jimenez-Pailhes, A.-S., Mustapha, R., Niki, T., Guigay, J., Pancré, V., de Launoit, Y., Busson, P., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju363 · Cited by 211
Self-citationRevisiting the Concept of Targeting NFAT to Control T Cell Immunity and Autoimmune Diseases
Lee, J.-U., Kim, L.-K., & Choi, J.-M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02747 · Cited by 190
“Recent studies have indicated that calcineurin inhibitors have a negative effect on regulatory T cell proliferation and function, which are necessary for immune tolerance (190, 191).”
BackgroundImmunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“In vitro studies showed Treg proliferation inhibition by tacrolimus and cyclosporine [221].”
BackgroundImpact of Immune-Modulatory Drugs on Regulatory T Cell
Furukawa, A., Wisel, S. A., & Tang, Q. (2016) · Transplantation · doi:10.1097/tp.0000000000001379 · Cited by 137
“Calcineurin inhibitors inhibit Treg proliferation in a dose-dependent fashion in vitro.(87) The FOXP3 promoter and enhancers contain multiple NFAT binding sites.”
BackgroundImmunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Yang, T., Braun, M., Lembke, W., McBlane, F., Kamerud, J., DeWall, S. L., Tarcsa, E., Fang, X., Hofer, L., Kavita, U., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.018 · Cited by 136
The Calcineurin Inhibitor Tacrolimus Specifically Suppresses Human T Follicular Helper Cells
Wallin, E. F., Hill, D. L., Linterman, M. A., & Wood, K. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01184 · Cited by 98
Scotta, C., Fanelli, G., Hoong, S. J., Romano, M., Lamperti, E. N., Sukthankar, M., Guggino, G., Fazekasova, H., Ratnasothy, K., Becker, P. D., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.128934 · Cited by 82
“Current evidence suggests that calcineurin inhibitors have markedly negative effects on circulating Tregs, mainly by interfering with IL-2 production and therefore affecting Treg function and survival.(11,12) Conversely, corticosteroids have been reported to increase Treg frequency and FOXP3 expression in patients wit…”
BackgroundDeng, X., Wang, Y., Jiang, L., Li, J., & Chen, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1023213 · Cited by 100
Possible alternative therapies for oral lichen planus cases refractory to steroid therapies
Yang, H., Wu, Y., Ma, H., Jiang, L., Zeng, X. Y., Dan, H., Zhou, Y. J., & Chen, Q. (2016) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2016.02.002 · Cited by 64
Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies
Chu, W. S., & Ng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658038 · Cited by 59
A versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
Kim, D. S., Park, Y., Choi, J., Park, S., Cho, M., & Kwok, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.696074 · Cited by 52
Jung, J., Overgaard, N. H., Burke, M., Isbel, N. M., Frazer, I. H., Simpson, F., & Wells, J. W. (2015) · International Journal of Cancer · doi:10.1002/ijc.29450 · Cited by 55
de Freitas, G. R. R., Fernandes, M. D. L., Agena, F., Jaluul, O., Silva, S. C., Lemos, F. B. C., Coelho, V. P. C. V., Elias, D.-N., & Galante, N. Z. (2018) · Aging and Disease · doi:10.14336/ad.2018.0318 · Cited by 52
“Calcineurin inhibitors (CNI) prevent TREG induction in vitro [46] in a dose dependent fashion [47], while mTOR inhibitors (mTORi) account for peripheral TREG generation in vitro [48] and TREG expansion in clinical practice [49].”
BackgroundNovel pathomechanisms in inflammatory neuropathies
Schafflick, D., Kieseier, B. C., Wiendl, H., & zu Hörste, G. M. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1001-8 · Cited by 53
The curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 52
P2X7R mutation disrupts the NLRP3-mediated Th program and predicts poor cardiac allograft outcomes
D’Addio, F., Vergani, A., Potena, L., Maestroni, A., Usuelli, V., Ben Nasr, M., Bassi, R., Tezza, S., Dellepiane, S., El Essawy, B., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94524 · Cited by 43
Kremer, J., Henschel, P., Simon, D., Riët, T., Falk, C. S., Hardtke‐Wolenski, M., Wedemeyer, H. H., Noyan, F., & Jaeckel, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1005582 · Cited by 45
“Tacrolimus (Tac) impairs Tregs in a dose-dependent manner by directly inhibiting Treg activation (21).”
BackgroundSingh, K., Rathore, U., Rai, M. K., Behera, M. R., Jain, N., Ora, M., Bhadauria, D., Sharma, S., Pande, G., Gambhir, S., et al. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s355881 · Cited by 42
“While the reduction of cytokines associated with inflammatory T lymphocyte populations with tacrolimus treatment can be expected, the reduction in the regulatory cytokine IL-10 (predominantly secreted by T regulatory lymphocytes) was intriguing, possibly related to pan-T lymphocyte suppressant effect of tacrolimus by…”
BackgroundShan, J., Feng, L., Li, Y., Sun, G., Chen, X., & Chen, P. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.07.006 · Cited by 35
“[2] Miroux C, Morales O, Ghazal K, Othman SB, de Launoit Y, Pancré V, et al.”
BackgroundLv, Q.-K., Liu, J., Li, S., Gao, Y., Lv, Y. L., Xu, Z., Huang, B., Xu, S. S., Yang, D., Zeng, Y., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161125985 · Cited by 33
“In previous reports, researchers found that the proliferation of Tregs can be inhibited by MMF in a dose-dependent manner [34], and MMF decreases the expanded B cell population through apoptosis [31].”
Askar, M. Z. (2014) · International Journal of Immunogenetics · doi:10.1111/iji.12106 · Cited by 33
Ono, E., dos Santos, A. M. N., Viana, P. O., Dinelli, M. I. S., Sass, N., Oliveira, L. G., Goulart, A. L., & de Moraes‐Pinto, M. I. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13143 · Cited by 30
“Calcineurin inhibitors can inhibit the proliferation of regulatory T cells and that could explain the observed decrease in the percentage of these cells (30).”
BackgroundLandwehr-Kenzel, S., Zobel, A., Hoffmann, H., Landwehr, N., Schmueck‐Henneresse, M., Schachtner, T., Roemhild, A., & Reinke, P. (2018) · Kidney International · doi:10.1016/j.kint.2018.01.021 · Cited by 28
Minimization or withdrawal of immunosuppressants in pediatric liver transplant recipients
Lin, N., Wang, H., Yeh, Y., Liu, C.-P., Che-Chuan, L., Tsai, H.-L., Chen, C.-Y., Chin, T., & Liu, C. (2015) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2015.08.043 · Cited by 28
Mao, R., Xiao, W. L., Liu, H., Chen, B., Yi, B., Kraj, P. J., & She, J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.03.013 · Cited by 29
Autologous regulatory T cells in clinical intraportal allogenic pancreatic islet transplantation
Bergström, M., Yao, M. H., Müller, M., Korsgren, O., von Zur‐Mühlen, B., & Lundgren, T. (2021) · Transplant International · doi:10.1111/tri.14163 · Cited by 29
“While standard immunosuppressive drugs can prevent graft rejection, some may hamper tolerance induction; commonly used immunosuppressants such as Basiliximab and Tacrolimus targets T-cell proliferation and function, which inhibits both effector T cells and Tregs [13,14].”
BackgroundImmunomodulation Stimulates the Innervation of Engineered Tooth Organ
Kökten, T., Bécavin, T., Keller, L., Weickert, J., Kuchler‐Bopp, S., & Lesot, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086011 · Cited by 27
Maffi, P., Berney, T., Nano, R., Niclauß, N., Bosco, D., Melzi, R., Mercalli, A., Magistretti, P., COBELLI, F. D., Battaglia, M., et al. (2014) · Transplantation · doi:10.1097/tp.0000000000000396 · Cited by 25
The Effect of Immunosuppressive Drugs on MDSCs in Transplantation
Yang, F., Li, Y., Zhang, Q., Tan, L., Peng, L., & Zhao, Y. X. (2018) · Journal of Immunology Research · doi:10.1155/2018/5414808 · Cited by 28
“Many proinflammatory transcription factors like nuclear factorκB (NFκB), activator protein 1 (AP1), the signal transducer and activator of transcription (STAT), CCAAT/enhancerbinding protein (C/EBP), and nuclear factor of activated T cells (NFAT) can interact with GR [72].”
BackgroundInfluentialFanigliulo, D., Lazzerini, P. E., Capecchi, P. L., Ulivieri, C., Baldari, C. T., & Laghi-Pasini, F. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2014.12.021 · Cited by 21
“More in detail, 9 studies [10–18] tested CsA in-vitro on cells from healthy human donors, but at variance with the present work, the effects of the drug on Tregs in terms of concomitant assessment of suppressive activity in MLR, cell proliferation, and FoxP3 expression have never been evaluated.”
BackgroundResultInfluentialLee, H., Kim, L.-K., & Choi, J. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.10.006 · Cited by 20
Mechanism of tacrolimus in the treatment of lupus nephritis
Wang, M., Zhou, J., Niu, Q., & Wang, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1331800 · Cited by 26
“For instance, the inhibition rate of Treg proliferation was about 35% at tacrolimus concentrations up to 40 ng/mL, while it could reach 70% at 400 ng/mL, and this inhibitory effect was independent of the CaN/NFAT pathway (Céline et al., 2012).”
BackgroundWang, Y., Tian, Y., Ding, Y., Wang, J., Yan, S., Zhou, L., Xie, H., Chen, H., Li, H., Zhang, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105096 · Cited by 19
“Rapamycin has beneficial effects on Tregs’ biology compared with calcineurin inhibitor in potentially attaining host hyporesponsiveness to an allograft [7,8].”
Regulatory T Cells Resist Cyclosporine-Induced Cell Death via CD44-Mediated Signaling Pathways
Ruppert, S. M., Falk, B. A., Long, S. A., & Bollyky, P. L. (2015) · International Journal of Cell Biology · doi:10.1155/2015/614297 · Cited by 20
“Miroux and colleagues found that CSA decreased both the activity and proliferation of Treg [41].”
BackgroundCardiovascular disease after transplantation: an emerging role of the immune system
Laecke, S. V., Malfait, T. L. A., Schepers, E., & Biesen, W. V. (2018) · Transplant International · doi:10.1111/tri.13160 · Cited by 24
“CNI impairs Treg proliferation and function after liver and kidney transplantation [43,44].”
BackgroundMiroux, C., Moralès, O., Ouaguia, L., Aoudjehane, L., Boleslawski, E., Pancré, V., de Launoit, Y., Calmus, Y., Conti, F., & Delhem, N. (2012) · Transplantation Proceedings · doi:10.1016/j.transproceed.2012.09.091 · Cited by 18
Self-citationCombinatory treatment using tacrolimus and a STAT3 inhibitor regulate Treg cells and plasma cells
Park, J., Kim, S., Hwang, S., Choi, S., Kwon, J. Y., Kwok, S., Cho, M., & Park, S. (2018) · International Journal of Immunopathology and Pharmacology · doi:10.1177/2058738418778724 · Cited by 18
Wang, X., Leveson-Gower, D. B., Gołąb, K., Wang, L., Marek-Trzonkowska, N. M., Krzystyniak, A., Wardowska, A., Millis, J. M., Trzonkowski, P., & Witkowski, P. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.02.015 · Cited by 17
“Treg proliferation in vitro [82,83].”
Immunosuppressive drugs affect induction of IFNy+ Treg in vitro
Daniel, V., Trojan, K., & Opelz, G. (2015) · Human Immunology · doi:10.1016/j.humimm.2015.11.006 · Cited by 20
“The phosphorylation of nuclear factor of activated T cell (NFaT) in Tregs was not altered by cyclosporine, suggesting an effect of this drug independent of the calcineurin pathway [10].”
BackgroundCarty, F., Corbett, J. M., da Cunha, J. P. M. C. M., Reading, J. L., Tree, T. I. M., Ting, A. E., Stubblefield, S. R., & English, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00645 · Cited by 18
The emerging role of regulatory T cells following lung transplantation
Gauthier, J. M., Harrison, M. S., Krupnick, A. S., Gelman, A. E., & Kreisel, D. (2019) · Immunological Reviews · doi:10.1111/imr.12801 · Cited by 19
Elmariah, H., Otoukesh, S., Kumar, A., Ali, H., Arslan, S., Shouse, G., Pourhassan, H., Nishihori, T., Faramand, R. G., Mishra, A., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.11.010 · Cited by 16
Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells
Maldini, C. R., Messana, A., Bendet, P. B., Camblin, A. J., Musenge, F. M., White, M. L., Rocha, J. J., Coholan, L. J., Karaca, C., Li, F., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.06.022 · Cited by 18
Sekiya, T., Kasahara, H., Takemura, R., Fujita, S., Kato, J., Doki, N., Katayama, Y., Ozawa, Y., Takada, S., Eto, T., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100808 · Cited by 16
Reduction in peripheral regulatory T cell population in childhood ocular type myasthenia gravis
Nishimura, T., Inaba, Y., Nakazawa, Y., Omata, T., Akasaka, M., Shirai, I., & Ichikawa, M. (2015) · Brain and Development · doi:10.1016/j.braindev.2014.12.007 · Cited by 16
“[33] Miroux C, Morales O, Ghazal K, Othman SB, de Launoit Y, Pancre V, et al.”
BackgroundResultTranscription factors in the development and treatment of immune disorders
Drinan, S. D., Bass, J. I. F., & Bass, J. I. F. (2023) · Transcription · doi:10.1080/21541264.2023.2294623 · Cited by 17
“However, given the central role of calcineurin in signaling across cell types, these drugs have wide-spread side effects [146,147].”
Chen, J., Li, H., Zhuo, J., Lin, Z., Hu, Z., He, C., Wu, X., Jin, Y., Lin, Z., Su, R., et al. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0267 · Cited by 18
Keyhanmehr, N., Motedayyen, H., & Eskandari, N. (2019) · Immunological Investigations · doi:10.1080/08820139.2019.1571506 · Cited by 14
“Although CsA inhibits the induction of immune tolerance, it decreases the risk of allograft rejection (Miroux et al., 2012a).”
BackgroundResultInfluentialAlqadi, R., Alqumia, A., Alhomoud, I. S., Alhowail, A., Aldubayan, M. A., Mohammed, H. A., Alhmoud, H., & Khan, R. A. (2024) · Transplant Immunology · doi:10.1016/j.trim.2024.102147 · Cited by 13
Nfatc2 and Tob1 Have Non-Overlapping Function in T Cell Negative Regulation and Tumorigenesis
May, S. L., Zhou, Q., Lewellen, M., Carter, C. M., Coffey, D. G., Highfill, S. L., Bucher, C. M., Matise, I., Morse, H. C., O’Sullivan, M. G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100629 · Cited by 14
“Previous studies showed that pharmacological inhibition of Nfat activity alters Treg function in vitro [27,28], suggesting this effect might be mediated by proteins distinct from Nfatc2.”
BackgroundInfluentialYoshinaga, T. T., Kfoury, J. R., Butzge, A. J., Olio, R. L., Hernandez‐Blazquez, F. J., Carreira, A. C. O., Gomes, C. D. O. M. S., Bianchi, P. K. F. D. C., Tabata, Y. A., & Hattori, R. S. (2021) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2021.03.002 · Cited by 12
Dahlqvist, G., Renaud, S., Barjon, C., Lefebvre, A., Aoudjehane, L., Horsmans, Y., Delhem, N., & Conti, F. (2020) · Immunobiology · doi:10.1016/j.imbio.2020.152031 · Cited by 12
Self-citationBeladjine, M., Albert, C., Sintes, M., Mekhloufi, G., Gueutin, C., Nicolas, V., Canette, A., Trichet, M., Tsapis, N., Michel, L., et al. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122870 · Cited by 11
Nasu, R., Nannya, Y., Shinohara, A., Ichikawa, M., & Kurokawa, M. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2027-y · Cited by 11
Park, S., Kım, K., Jang, J. H., Kim, S. J., Kim, W. S., & Jung, C. W. (2016) · Oncotarget · doi:10.18632/oncotarget.10988 · Cited by 13
Du, Y., Yang, C., Chen, M., Ruan, J., Huang, Y., Chen, F., & Han, B. (2020) · Hematology · doi:10.1080/16078454.2020.1852763 · Cited by 10
Benazzo, A., Cho, A., Nechay, A., Schwarz, S., Frommlet, F., Wekerle, T., Höetzenecker, K., & Jaksch, P. (2021) · Trials · doi:10.1186/s13063-020-04843-9 · Cited by 10
“NFAT activates IL-2 transcription, which regulates proliferation and maturation for all T cell subtypes, including Tregs [24].”
BackgroundInfluentialT Cell immune reconstitution after allo-HSCT: key factors and implications
Dai, W., Dong, F., Cheng, T., & Hao, S. (2025) · Blood Science · doi:10.1097/bs9.0000000000000261 · Cited by 10
“56,57 Mycophenolate mofetil significantly suppressed the expansion of V δ 2+ T cells and attenuated their cytotoxic activity against EBV-transformed malignant cells, consequently promoting EBV reactivation.”
Landwehr-Kenzel, S., Zobel, A., Schmitt-Knosalla, I., Forke, A., Hoffmann, H., Schmueck‐Henneresse, M., Klopfleisch, R., Volk, H., & Reinke, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.716629 · Cited by 10
“Accordingly, the current paradigm holds that under most circumstances CSA leads to reduced de novo conversion of allospecific Tregs (45), reduced frequency of circulating tTregs (46), and reduced suppressive capacities (47).”
BackgroundChallenges of recurrent hepatitis C in the liver transplant patient
Dhanasekaran, R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i13.3391 · Cited by 8
Park, M.-Y., Choo, Y., Jeon, S. H., Jang, W., Lee, J., Park, J., & Kim, C. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106553 · Cited by 8
Tolerance, immunosuppression, and immune modulation: impacts on lung allograft survival
Shepherd, H. M., Gauthier, J. M., & Kreisel, D. (2021) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000871 · Cited by 9
“Examples include peri-operative global T cell depletion therapies, which eliminate Tregs and central memory CD8þ T cells, as well as calcineurin inhibitors, which suppress Treg activation and decrease NO production [33,34].”
BackgroundSafa, K., Chandran, S., & Wojciechowski, D. (2015) · Drugs · doi:10.1007/s40265-015-0487-6 · Cited by 8
Ding, L., Zhu, H., Yang, Y., Yan, H.-M., Zhang, H., Han, D., Wang, Z., Zheng, X.-L., Liu, J., Zhu, L., et al. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.01.011 · Cited by 8
Shahi, A., Salehi, S., Afzali, S., Afrakoti, L. G. M. P., Esmaeili, M., Bagherpour, F., Aghsaeifard, Z., Dehghani, S., Pourmand, G., & Amirzargar, A. A. (2021) · BioMed Research International · doi:10.1155/2021/6627909 · Cited by 7
“But the data about the effect of CNIs on Tregs are controversial and some other studies suggested the more beneficial impact of Tac on Treg cells [40, 46].”
ResultCyclosporine A for the treatment of refractory nephrotic syndrome with renal dysfunction
Gao, X., Ma, Y., Sun, L., Chen, D., Mei, C., & Xu, C. (2013) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2013.1446 · Cited by 7
“Cyclosporine A (CsA) is an immunosuppressant agent that is widely used in clinical practice, predominantly for the prevention of rejection in various types of organ transplantation (3,4).”
A benzoxazole derivative PO‐296 inhibits T lymphocyte proliferation by the JAK3/STAT5 signal pathway
Luo, X., Zhou, H., Wang, S., Xiong, J., Mo, C., Guo, H., Wang, Y., Yang, S., Li, L., Zou, Q., et al. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28195 · Cited by 7
Regulatory T Cells for the Induction of Transplantation Tolerance
Que, W., & Li, X. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-6407-9_15 · Cited by 10
Magnusson, J. M., Bobbio, E., Danielsson, C., Wallinder, A., Dellgren, G., & Bollano, E. (2022) · Transplantation Proceedings · doi:10.1016/j.transproceed.2021.11.031 · Cited by 7
Preliminary Study of Interaction of Clarithromycin with Tacrolimus in Cats
KATAYAMA, M., USHIO, T., SHIMAMURA, S., Okamura, Y., & UZUKA, Y. (2014) · Journal of Veterinary Medical Science · doi:10.1292/jvms.14-0101 · Cited by 6
Chemically conjugated novel liposomal formulation for intravenous delivery of cyclosporin A
Park, Y., Min, K. A., Song, Y., Ham, S., & Kim, C. (2016) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2016.02.008 · Cited by 5
Motiee, M., Hosseini, A. Z., & Soudi, S. (2021) · Tuberculosis · doi:10.1016/j.tube.2021.102163 · Cited by 7
Katsumata, H., Miyairi, S., Ikemiyagi, M., Hirai, T., Fukuda, H., Kanzawa, T., Ishii, R., Saiga, K., Ishii, Y., Omoto, K., et al. (2018) · Transplant International · doi:10.1111/tri.13390 · Cited by 6
“[33] reported CNIs inhibit Treg proliferation in a dose-dependent manner under in vitro culture conditions.”
Ghazal, K., Moralès, O., Barjon, C., Dahlqvist, G., Aoudjehane, L., Ouaguia, L., Delhem, N., & Conti, F. (2019) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2018.10.005 · Cited by 5
Self-citationDu, Y., Huang, Y., Zhou, W., Liu, X., Chen, F., Yang, C., Chen, M., Ruan, J., & Han, B. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s275975 · Cited by 5
Gupta, P., Ryman, J. T., Jawa, V., & Meibohm, B. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070845 · Cited by 4
“Previously, tacrolimus was shown to induce tolerance by increasing the proliferation of T regs in liver and kidney transplant patients [68,69].”
Cyclosporin A inhibits PDGF-BB induced hyaluronan synthesis in orbital fibroblasts
Galgoczi, E., Molnár, Z., Katkó, M., Ujhelyi, B., Steiber, Z., & Nagy, E. V. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111045 · Cited by 3
Zhang, Y., Chen, J., Huang, C., Xu, Y., Ma, R., Lei, H., Gao, H., Ma, Y., Li, Q., Guan, S., et al. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.114944 · Cited by 3
Metzker, M., Shipkova, M., von Ahsen, N., Andag, R., Abe, M., Canzler, O., Klett, C., Leicht, S., Olbricht, C. J., & Wieland, E. (2016) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2016.05.019 · Cited by 3
Meisel, E., Bielopolski, D., Steinmetz, T., Agur, T., Lichtenberg, S., Goldman, S. N., Herman‐Edelstein, M., Nesher, E., Rahamimov, R., & Rozen‐Zvi, B. (2024) · Clinical Transplantation · doi:10.1111/ctr.15460 · Cited by 2
Leino, A. D., & Pai, M. P. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00923-w · Cited by 2
de Freitas, G. R. R., Fernandes, M. D. L., Agena, F., Lemos, F. B. C., de Paula, F. J., Coelho, V. P. C. V., David-Neto, E., & Galante, N. Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1405855 · Cited by 2
Mao, R., Liu, H., Yi, B., Purohit, S. B., Kuczma, M., Kraj, P. J., & She, J. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.08.020 · Cited by 2
Calcineurin Inhibitor - A Necessary Evil: Pharmacogenetical Approach to a Promising Future
Zhang, L., Gu, C., Huang, S., Rong, R., & Zhu, T. (2015) · SM Journal of Urology · doi:10.36876/smju.1008 · Cited by 2
Rodriguez, N. T., Lee, J., Flynn, L., Murray, F., Devlin, S. M., Soto, C., Cho, C., Dahi, P. B., Giralt, S., Perales, M., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.05.008 · Cited by 3
Anft, M., Zgoura, P., Skrzypczyk, S., Dürr, M., Viebahn, R., Westhoff, T. H., Stervbo, U., & Babel, N. (2024) · Frontiers in Transplantation · doi:10.3389/frtra.2024.1405070 · Cited by 2
Regulatory T Cells and Nanomaterials: Dual Perspectives in Therapeutics and Immunomodulation
Chen, Y. H., Huang, H., Wang, X., Yu, X., Huang, Z., Jin, Z., Chen, C., Chen, Y., Blazar, B. R., Xu, Y., et al. (2025) · Small Science · doi:10.1002/smsc.202500481 · Cited by 2
Ren, D., Chauveau, G. A., Cabon, E., Vendomèle, J., Vignal‐Clermont, C., Saliba, H., Ail, D., Dalkara, D., & Fisson, S. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101443 · Cited by 1
Induction of liver transplant immune tolerance in an outbred rat strain model using tacrolimus
Park, M.-J., Na, H. S., Joo, Y.-S., Cho, K.-H., Kim, S. Y., Choi, J. W., Baek, J.-A., Choi, J. Y., You, Y. K., & Cho, M. (2023) · Laboratory Animal Research · doi:10.1186/s42826-023-00156-5 · Cited by 1
“In addition, FK506 suppressed pro-inflammatory T helper (Th)1/Th17 responses [18, 19] and Foxp3 + Treg [20].”
BackgroundLeung, M. L., Barrett‐Chan, E., Levings, M. K., Vercauteren, S., & Blydt‐Hansen, T. D. (2025) · Pediatric Transplantation · doi:10.1111/petr.70041 · Cited by 2
“In vitro studies have found that of the CNIs, tacrolimus better supports Treg function compared to cyclosporine and neither affected Tregs to a significantly greater extent than Teff [49].”
Immune Suppression in Lung Disease: Lung Transplantation and HIV
McGinniss, J. E., Bernasconi, E., Twigg, H. L., & Morris, A. (2022) · Respiratory medicine · doi:10.1007/978-3-030-87104-8_10 · Cited by 1
Basosquamous Cell Carcinoma Developing from a Renal Transplantation Recipient
Tsukada, A., Fujimura, T., Furudate, S., Kambayashi, Y., Hashimoto, A., & Aiba, S. (2012) · Case Reports in Dermatology · doi:10.1159/000345095
The Immune Response to the Allograft
Carty, F., & English, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801734-0.00018-7
Yoshinaga, T. T. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.10.2019.tde-17102018-082442
de Freitas, G. R. R. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2020.tde-31012020-115923
Kim, D. S., Park, Y., Choi, J.-W., Park, S., Cho, M., & Kwok, S. (2020) · Research Square · doi:10.21203/rs.3.rs-131493/v1
Du, Y., Huang, Y., Zhou, W., Liu, X., Chen, F., Yang, C. C., Chen, M., Ruan, J., & Han, B. (2020) · doi:10.21203/rs.3.rs-41969/v1
“However, tacrolimus may have different way of action from that of CsA because we observed the decrease level of Treg cells after CsA treatment was signi cant improved after full dose of tacrolimus in patients who responded[13, 23].”
Background
Metadata
- Authors
- Miroux, C., Morales, O., Ghazal, K., Othman, S. B., de Launoit, Y., Pancré, V., Conti, F., & Delhem, N.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Venue
- Transplantation
- Published
- 2012-07-27
- Volume
- 94
- Issue
- 2
- Pages
- 123-131
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W1995250629
- Cited by
- 117
- References
- 46
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 9 · 2023: 7 · 2022: 7 · 2021: 13 · 2020: 9 · 2019: 6 · 2018: 11 · 2017: 3 · 2016: 5 · 2015: 10 · 2014: 14 · 2013: 4 · 2012: 2
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Transplantation (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- cyclosporine, tacrolimus, regulatory T cells, Treg proliferation, immunosuppression, liver transplantation, recurrent hepatitis C, calcineurin inhibitors, NIM811, interleukin-2, graft rejection, Treg suppressive function
- MeSH terms
- Cells, Cultured, Humans, Immunosuppressive Agents, Lymphocyte Activation, Phosphorylation, Liver Transplantation, Immunophenotyping, Cytokines, Tacrolimus, Cyclosporine, T-Lymphocytes, Regulatory, NFATC Transcription Factors, Calcineurin Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.